Development of novel adenoviral vectors to overcome challenges observed with HAdV-5-based constructs

Molecular Therapy

Volumn 24, Issue 1, 2016, Pages 6-16

  Alonso Padilla, Julio ^a   Papp, Tibor ^b   Kaján, Gyozo L ^b   Benko, Mária ^b   Havenga, Menzo ^c   Lemckert, Angelique ^c   Harrach, Balázs ^b   Baker, Andrew H ^a,d  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c Bioscience Park Leiden   (Netherlands)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR;

ADENOVIRIDAE; ARTICLE; BOVINE ADENOVIRUS 2; CANINE ADENOVIRUS 2; CHICK EMBRYO LETHAL ORPHAN VIRUS; FOWL ADENOVIRUS; FOWL ADENOVIRUS 10; FOWL ADENOVIRUS 4; FOWL ADENOVIRUS 8; FOWL ADENOVIRUS 9; FOWL ADENOVIRUS C; GENE THERAPY; GENE TRANSFER; HUMAN; HUMAN ADENOVIRUS 11; HUMAN ADENOVIRUS 26; HUMAN ADENOVIRUS 28; HUMAN ADENOVIRUS 3; HUMAN ADENOVIRUS 35; HUMAN ADENOVIRUS 48; HUMAN ADENOVIRUS 49; HUMAN ADENOVIRUS 5; HUMAN ADENOVIRUS 50; HUMAN ADENOVIRUS B; HUMAN ADENOVIRUS D; HUMAN ADENOVIRUS E; HUMAN ADENOVIRUS F; IMMUNE RESPONSE; INNATE IMMUNITY; LIVER TOXICITY; NONHUMAN; OVINE ADENOVIRUS 7; PORCINE ADENOVIRUS 3; PORCINE ADENOVIRUS 5; SIMIAN VIRUS; VIRUS CAPSID; GENE VECTOR; GENETICS; HUMAN ADENOVIRUS C; IMMUNOLOGY; TOXICITY;

ADENOVIRUSES, HUMAN; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; IMMUNITY, INNATE;

EID: 84957848237     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.194     Document Type: Review

References (209)

1. Harrach, B, Benko, M, Both, GW, Brown, M, Davison, AJ, Echavarría, M., et al. (2011). Adenoviridae. In: King, AMQ, Adams MJ, Carstens, EB, and Lefkowitz, EJ (eds). Virus Taxonomy. Elsevier: Oxford. pp. 125-141
2. Harrach, B. . Accessed 1 September 2015
3. Benkö, M (2008). Adenoviruses: pathogenesis. In: Mahy, BWJ, Regenmortel, MHV (eds). Encyclopedia of Virology, Third edition, vol. 1. Elsevier: Oxford. pp. 24-29
4. Liu, H, Jin, L, Koh, SB, Atanasov, I, Schein, S, Wu, L., et al. (2010). Atomic structure of human adenovirus by cryo-EM reveals interactions among protein networks. Science 329: 1038-1043
5. Reddy, VS, Natchiar, SK, Stewart, PL and Nemerow, GR (2010). Crystal structure of human adenovirus at 3.5 A resolution. Science 329: 1071-1075
6. Benevento, M, Di Palma, S, Snijder, J, Moyer, CL, Reddy, VS, Nemerow, GR., et al. (2014). Adenovirus composition, proteolysis, and disassembly studied by in-depth qualitative and quantitative proteomics. J Biol Chem 289: 11421-11430
7. Reddy, VS and Nemerow, GR (2014). Structures and organization of adenovirus cement proteins provide insights into the role of capsid maturation in virus entry and infection. Proc Natl Acad Sci USA 111: 11715-11720
8. Rux, JJ, Kuser, PR and Burnett, RM (2003). Structural and phylogenetic analysis of adenovirus hexons by use of high-resolution x-ray crystallographic, molecular modeling, and sequence-based methods. J Virol 77: 9553-9566
9. Bergelson, JM, Cunningham, JA, Droguett, G, Kurt-Jones, EA, Krithivas, A, Hong, JS., et al. (1997). Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275: 1320-1323
10. Wickham, TJ, Filardo, EJ, Cheresh, DA and Nemerow, GR (1994). Integrin alpha v beta 5 selectively promotes adenovirus mediated cell membrane permeabilization. J Cell Biol 127: 257-264
11. Wolfrum, N and Greber, UF (2013). Adenovirus signalling in entry. Cell Microbiol 15: 53-62
12. Arnberg, N (2012). Adenovirus receptors: implications for targeting of viral vectors. Trends Pharmacol Sci 33: 442-448
13. Burckhardt, CJ, Suomalainen, M, Schoenenberger, P, Boucke, K, Hemmi, S and Greber, UF (2011). Drifting motions of the adenovirus receptor CAR and immobile integrins initiate virus uncoating and membrane lytic protein exposure. Cell Host Microbe 10: 105-117
14. Vectors used in gene therapy clinical trials. The Journal of Gene Medicine, 2015. John Wiley & Sons Ltd. . Accessed 1 September 2015
15. Appaiahgari, MB and Vrati, S (2015). Adenoviruses as gene/vaccine delivery vectors: promises and pitfalls. Expert Opin Biol Ther 15: 337-351
16. Pearson, S, Jia, H and Kandachi, K (2004). China approves first gene therapy. Nat Biotechnol 22: 3-4
17. Wilson, JM (2009). Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency. Mol Genet Metab 96: 151-157
18. Chorny, M, Fishbein, I, Tengood, JE, Adamo, RF, Alferiev, IS and Levy, RJ (2013). Sitespecific gene delivery to stented arteries using magnetically guided zinc oleate-based nanoparticles loaded with adenoviral vectors. FASEB J 27: 2198-2206
19. Van Kampen, KR, Shi, Z, Gao, P, Zhang, J, Foster, KW, Chen, DT., et al. (2005). Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 23: 1029-1036
20. George, SJ, Wan, S, Hu, J, MacDonald, R, Johnson, JL and Baker, AH (2011). Sustained reduction of vein graft neointima formation by ex vivo TIMP-3 gene therapy. Circulation 124(suppl. 11): S135-S142
21. Ranki, T and Hemminki, A (2010). Serotype chimeric human adenoviruses for cancer gene therapy. Viruses 2: 2196-2212
22. Hendrickx, R, Stichling, N, Koelen, J, Kuryk, L, Lipiec, A and Greber, UF (2014). Innate immunity to adenovirus. Hum Gene Ther 25: 265-284
23. Ilan, Y, Droguett, G, Chowdhury, NR, Li, Y, Sengupta, K, Thummala, NR., et al. (1997). Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression. Proc Natl Acad Sci USA 94: 2587-2592
24. Schaack, J, Bennett, ML, Shapiro, GS, DeGregori, J, McManaman, JL and Moorhead, JW (2011). Strong foreign promoters contribute to innate inflammatory responses induced by adenovirus transducing vectors. Virology 412: 28-35
25. Aldhamen, YA, Seregin, SS and Amalfitano, A (2011). Immune recognition of gene transfer vectors: focus on adenovirus as a paradigm. Front Immunol 2: 40
26. Machitani, M, Yamaguchi, T, Shimizu, K, Sakurai, F, Katayama, K, Kawabata, K., et al. (2011). Adenovirus vector-derived VA-RNA-mediated innate immune responses. Pharmaceutics 3: 338-353
27. Appledorn, DM, Patial, S, McBride, A, Godbehere, S, Van Rooijen, N, Parameswaran, N., et al. (2008). Adenovirus vector-induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo. J Immunol 181: 2134-2144
28. Perreau, M, Welles, HC, Pellaton, C, Gjoksi, B, Potin, L, Martin, R., et al. (2012). The number of Toll-like receptor 9-agonist motifs in the adenovirus genome correlates with induction of dendritic cell maturation by adenovirus immune complexes. J Virol 86: 6279-6285
29. Minamitani, T, Iwakiri, D and Takada, K (2011). Adenovirus virus-associated RNAs induce type I interferon expression through a RIG-I-mediated pathway. J Virol 85: 4035-4040
30. Khare, R, Chen, CY, Weaver, EA and Barry, MA (2011). Advances and future challenges in adenoviral vector pharmacology and targeting. Curr Gene Ther 11: 241-258
31. Lyons, M, Onion, D, Green, NK, Aslan, K, Rajaratnam, R, Bazan-Peregrino, M., et al. (2006). Adenovirus type 5 interactions with human blood cells may compromise systemic delivery. Mol Ther 14: 118-128
32. Carlisle, RC, Di, Y, Cerny, AM, Sonnen, AF, Sim, RB, Green, NK., et al. (2009). Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virusadenovirus receptor and complement receptor 1. Blood 113: 1909-1918
33. Seiradake, E, Henaff, D, Wodrich, H, Billet, O, Perreau, M, Hippert, C., et al. (2009). The cell adhesion molecule CAR and sialic acid on human erythrocytes influence adenovirus in vivo biodistribution. PLoS Pathog 5: e1000277
34. Xu, Z, Tian, J, Smith, JS and Byrnes, AP (2008). Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement. J Virol 82: 11705-11713
35. Khare, R, Hillestad, ML, Xu, Z, Byrnes, AP and Barry, MA (2013). Circulating antibodies and macrophages as modulators of adenovirus pharmacology. J Virol 87: 3678-3686
36. Qiu, Q, Xu, Z, Tian, J, Moitra, R, Gunti, S, Notkins, AL., et al. (2015). Impact of natural IgM concentration on gene therapy with adenovirus type 5 vectors. J Virol 89: 3412-3416
37. Waddington, SN, McVey, JH, Bhella, D, Parker, AL, Barker, K, Atoda, H., et al. (2008). Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132: 397-409
38. Kalyuzhniy, O, Di Paolo, NC, Silvestry, M, Hofherr, SE, Barry, MA, Stewart, PL., et al. (2008). Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc Natl Acad Sci USA 105: 5483-5488
39. Vigant, F, Descamps, D, Jullienne, B, Esselin, S, Connault, E, Opolon, P., et al. (2008). Substitution of hexon hypervariable region 5 of adenovirus serotype 5 abrogates blood factor binding and limits gene transfer to liver. Mol Ther 16: 1474-1480
40. Alba, R, Bradshaw, AC, Parker, AL, Bhella, D, Waddington, SN, Nicklin, SA., et al. (2009). Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood 114: 965-971
41. Jonsson, MI, Lenman, AE, Frängsmyr, L, Nyberg, C, Abdullahi, M and Arnberg, N (2009). Coagulation factors IX and X enhance binding and infection of adenovirus types 5 and 31 in human epithelial cells. J Virol 83: 3816-3825
42. Lenman, A, Müller, S, Nygren, MI, Frängsmyr, L, Stehle, T and Arnberg, N (2011). Coagulation factor IX mediates serotype-specific binding of species A adenoviruses to host cells. J Virol 85: 13420-13431
43. Doronin, K, Flatt, JW, Di Paolo, NC, Khare, R, Kalyuzhniy, O, Acchione, M., et al. (2012). Coagulation factor X activates innate immunity to human species C adenovirus. Science 338: 795-798
44. Xu, Z, Qiu, Q, Tian, J, Smith, JS, Conenello, GM, Morita, T., et al. (2013). Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement. Nat Med 19: 452-457
45. Eichholz, K, Mennechet, FJ and Kremer, EJ (2015). Human coagulation factor X-adenovirus type 5 complexes poorly stimulate an innate immune response in human mononuclear phagocytes. J Virol 89: 2884-2891
46. Ganesan, LP, Mohanty, S, Kim, J, Clark, KR, Robinson, JM and Anderson, CL (2011). Rapid and efficient clearance of blood-borne virus by liver sinusoidal endothelium. PLoS Pathog 7: e1002281
47. Alemany, R, Suzuki, K and Curiel, DT (2000). Blood clearance rates of adenovirus type 5 in mice. J Gen Virol 81: 2605-2609
48. Piccolo, P, Vetrini, F, Mithbaokar, P, Grove, NC, Bertin, T, Palmer, D., et al. (2013). SR-A and SREC-I are Kupffer and endothelial cell receptors for helper-dependent adenoviral vectors. Mol Ther 21: 767-774
49. Mocanu, JD, Yip, KW, Alajez, NM, Shi, W, Li, JH, Lunt, SJ., et al. (2007). Imaging the modulation of adenoviral kinetics and biodistribution for cancer gene therapy. Mol Ther 15: 921-929
50. Piccolo, P, Annunziata, P, Mithbaokar, P and Brunetti-Pierri, N (2014). SR-A and SREC-I binding peptides increase HDAd-mediated liver transduction. Gene Ther 21: 950-957
51. Khare, R, May, SM, Vetrini, F, Weaver, EA, Palmer, D, Rosewell, A., et al. (2011). Generation of a Kupffer cell-evading adenovirus for systemic and liver-directed gene transfer. Mol Ther 19: 1254-1262
52. Xu, W, Zhang, Z, Yang, Y, Hu, Z, Wang, CH, Morgan, M., et al. (2014). Ad5/48 hexon oncolytic virus expressing sTGFβRIIFc produces reduced hepatic and systemic toxicities and inhibits prostate cancer bone metastases. Mol Ther 22: 1504-1517
53. Lasaro, MO and Ertl, HC (2009). New insights on adenovirus as vaccine vectors. Mol Ther 17: 1333-1339
54. Zak, DE, Andersen-Nissen, E, Peterson, ER, Sato, A, Hamilton, MK, Borgerding, J., et al. (2012). Merck Ad5/HIV induces broad innate immune activation that predicts CD8 T-cell responses but is attenuated by preexisting Ad5 immunity. Proc Natl Acad Sci USA 109: E3503-E3512
55. Zhang, S, Huang, W, Zhou, X, Zhao, Q, Wang, Q and Jia, B (2013). Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults. J Med Virol 85: 1077-1084
56. Barouch, DH, Kik, SV, Weverling, GJ, Dilan, R, King, SL, Maxfield, LF., et al. (2011). International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 29: 5203-5209
57. Bradley, RR, Lynch, DM, Iampietro, MJ, Borducchi, EN and Barouch, DH (2012). Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection. J Virol 86: 625-629
58. Roberts, DM, Nanda, A, Havenga, MJ, Abbink, P, Lynch, DM, Ewald, BA., et al. (2006). Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441: 239-243
59. Gall, J, Kass-Eisler, A, Leinwand, L and Falck-Pedersen, E (1996). Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes. J Virol 70: 2116-2123
60. Fausther-Bovendo, H and Kobinger, GP (2014). Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, whats important?. Hum Vaccin Immunother 10: 2875-2884
61. Sumida, SM, Truitt, DM, Lemckert, AA, Vogels, R, Custers, JH, Addo, MM., et al. (2005). Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol 174: 7179-7185
62. Miyazawa, N, Leopold, PL, Hackett, NR, Ferris, B, Worgall, S, Falck-Pedersen, E., et al. (1999). Fiber swap between adenovirus subgroups B and C alters intracellular trafficking of adenovirus gene transfer vectors. J Virol 73: 6056-6065
63. Teigler, JE, Kagan, JC and Barouch, DH (2014). Late endosomal trafficking of alternative serotype adenovirus vaccine vectors augments antiviral innate immunity. J Virol 88: 10354-10363
64. Smith, CA, Woodruff, LS, Rooney, C and Kitchingman, GR (1998). Extensive crossreactivity of adenovirus-specific cytotoxic T cells. Hum Gene Ther 9: 1419-1427
65. Molinier-Frenkel, V, Gahery-Segard, H, Mehtali, M, Le Boulaire, C, Ribault, S, Boulanger, P., et al. (2000). Immune response to recombinant adenovirus in humans: capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes. J Virol 74: 7678-7682
66. Heemskerk, B, Veltrop-Duits, LA, Van Vreeswijk, T, ten Dam, MM, Heidt, S, Toes, RE., et al. (2003). Extensive cross-reactivity of CD4+ adenovirus-specific T cells: implications for immunotherapy and gene therapy. J Virol 77: 6562-6566
67. Hutnick, NA, Carnathan, D, Demers, K, Makedonas, G, Ertl, HC and Betts, MR (2010). Adenovirus-specific human T cells are pervasive, polyfunctional, and cross-reactive. Vaccine 28: 1932-1941
68. Tang, J, Olive, M, Pulmanausahakul, R, Schnell, M, Flomenberg, N, Eisenlohr, L., et al. (2006). Human CD8+ cytotoxic T cell responses to adenovirus capsid proteins. Virology 350: 312-322
69. Olive, M, Eisenlohr, L, Flomenberg, N, Hsu, S and Flomenberg, P (2002). The adenovirus capsid protein hexon contains a highly conserved human CD4+ T-cell epitope. Hum Gene Ther 13: 1167-1178
70. Leen, AM, Sili, U, Vanin, EF, Jewell, AM, Xie, W, Vignali, D., et al. (2004). Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells. Blood 104: 2432-2440
71. Joshi, A, Tang, J, Kuzma, M, Wagner, J, Mookerjee, B, Filicko, J., et al. (2009). Adenovirus DNA polymerase is recognized by human CD8+ T cells. J Gen Virol 90: 84-94
72. Osada, T, Yang, XY, Hartman, ZC, Glass, O, Hodges, BL, Niedzwiecki, D., et al. (2009). Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity. Cancer Gene Ther 16: 673-682
73. Perreau, M and Kremer, EJ (2005). Frequency, proliferation, and activation of human memory T cells induced by a nonhuman adenovirus. J Virol 79: 14595-14605
74. Seregin, SS and Amalfitano, A (2010). Improving adenovirus based gene transfer: strategies to accomplish immune evasion. Viruses 2: 2013-2036
75. Seregin, SS, Appledorn, DM, McBride, AJ, Schuldt, NJ, Aldhamen, YA, Voss, T., et al. (2009). Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy. Mol Ther 17: 685-696
76. Fontanellas, A, Hervás-Stubbs, S, Mauleón, I, Dubrot, J, Mancheño, U, Collantes, M., et al. (2010). Intensive pharmacological immunosuppression allows for repetitive liver gene transfer with recombinant adenovirus in nonhuman primates. Mol Ther 18: 754-765
77. Cerullo, V, Seiler, MP, Mane, V, Brunetti-Pierri, N, Clarke, C, Bertin, TK., et al. (2007). Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors. Mol Ther 15: 378-385
78. Brunetti-Pierri, N, Palmer, DJ, Beaudet, AL, Carey, KD, Finegold, M and Ng, P (2004). Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum Gene Ther 15: 35-46
79. Seregin, SS, Aldhamen, YA, Appledorn, DM, Hartman, ZC, Schuldt, NJ, Scott, J., et al. (2010). Adenovirus capsid-display of the retro-oriented human complement inhibitor DAF reduces Ad vector-triggered immune responses in vitro and in vivo. Blood 116: 1669-1677
80. Farrow, AL, Rachakonda, G, Gu, L, Krendelchtchikova, V, Nde, PN, Pratap, S., et al. (2014). Immunization with Hexon modified adenoviral vectors integrated with gp83 epitope provides protection against Trypanosoma cruzi infection. PLoS Negl Trop Dis 8: e3089
81. McConnell, MJ, Hanna, PC and Imperiale, MJ (2006). Cytokine response and survival of mice immunized with an adenovirus expressing Bacillus anthracis protective antigen domain 4. Infect Immun 74: 1009-1015
82. Belousova, N, Krendelchtchikova, V, Curiel, DT and Krasnykh, V (2002). Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein. J Virol 76: 8621-8631
83. Seregin, SS and Amalfitano, A (2009). Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors. Expert Opin Biol Ther 9: 1521-1531
84. Capasso, C, Garofalo, M, Hirvinen, M and Cerullo, V (2014). The evolution of adenoviral vectors through genetic and chemical surface modifications. Viruses 6: 832-855
85. Green, NK, Herbert, CW, Hale, SJ, Hale, AB, Mautner, V, Harkins, R., et al. (2004). Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther 11: 1256-1263
86. Doronin, K, Shashkova, EV, May, SM, Hofherr, SE and Barry, MA (2009). Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus. Hum Gene Ther 20: 975-988
87. Kreppel, F and Kochanek, S (2008). Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide. Mol Ther 16: 16-29
88. Matsui, H, Sakurai, F, Katayama, K, Yamaguchi, T, Okamoto, S, Takahira, K., et al. (2012). A hexon-specific PEGylated adenovirus vector utilizing blood coagulation factor X. Biomaterials 33: 3743-3755
89. Suzuki-Kouyama, E, Katayama, K, Sakurai, F, Yamaguchi, T, Kurachi, S, Kawabata, K., et al. (2011). Hexon-specific PEGylated adenovirus vectors utilizing avidin-biotin interaction. Biomaterials 32: 1724-1730
90. Prill, JM, Subr, V, Pasquarelli, N, Engler, T, Hoffmeister, A, Kochanek, S., et al. (2014). Traceless bioresponsive shielding of adenovirus hexon with HPMA copolymers maintains transduction capacity in vitro and in vivo. PLoS One 9: e82716
91. Krasnykh, VN, Mikheeva, GV, Douglas, JT and Curiel, DT (1996). Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol 70: 6839-6846
92. Zabner, J, Chillon, M, Grunst, T, Moninger, TO, Davidson, BL, Gregory, R., et al. (1999). A chimeric type 2 adenovirus vector with a type 17 fiber enhances gene transfer to human airway epithelia. J Virol 73: 8689-8695
93. Havenga, MJ, Lemckert, AA, Grimbergen, JM, Vogels, R, Huisman, LG, Valerio, D., et al. (2001). Improved adenovirus vectors for infection of cardiovascular tissues. J Virol 75: 3335-3342
94. Lecollinet, S, Gavard, F, Havenga, MJ, Spiller, OB, Lemckert, A, Goudsmit, J., et al. (2006). Improved gene delivery to intestinal mucosa by adenoviral vectors bearing subgroup B and d fibers. J Virol 80: 2747-2759
95. Coughlan, L, Alba, R, Parker, AL, Bradshaw, AC, McNeish, IA, Nicklin, SA., et al. (2010). Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses 2: 2290-2355
96. Granio, O, Ashbourne Excoffon, KJ, Henning, P, Melin, P, Norez, C, Gonzalez, G., et al. (2010). Adenovirus 5-fiber 35 chimeric vector mediates efficient apical correction of the cystic fibrosis transmembrane conductance regulator defect in cystic fibrosis primary airway epithelia. Hum Gene Ther 21: 251-269
97. Parker, AL, White, KM, Lavery, CA, Custers, J, Waddington, SN and Baker, AH (2013). Pseudotyping the adenovirus serotype 5 capsid with both the fibre and penton of serotype 35 enhances vascular smooth muscle cell transduction. Gene Ther 20: 1158-1164
98. Guse, K, Suzuki, M, Sule, G, Bertin, TK, Tyynismaa, H, Ahola-Erkkilä, S., et al. (2012). Capsid-modified adenoviral vectors for improved muscle-directed gene therapy. Hum Gene Ther 23: 1065-1070
99. Smith, TA, Idamakanti, N, Marshall-Neff, J, Rollence, ML, Wright, P, Kaloss, M., et al. (2003). Receptor interactions involved in adenoviral-mediated gene delivery after systemic administration in non-human primates. Hum Gene Ther 14: 1595-1604
100. Nicol, CG, Graham, D, Miller, WH, White, SJ, Smith, TA, Nicklin, SA., et al. (2004). Effect of adenovirus serotype 5 fiber and penton modifications on in vivo tropism in rats. Mol Ther 10: 344-354
101. Bruder, JT, Semenova, E, Chen, P, Limbach, K, Patterson, NB, Stefaniak, ME., et al. (2012). Modification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responses. PLoS One 7: e33920
102. Bruder, JT, Chen, P, Semenova, E, Thomas, CA, Konovalova, S, Ekberg, G., et al. (2013). Identification of a suppressor mutation that improves the yields of hexon-modified adenovirus vectors. J Virol 87: 9661-9671
103. Baden, LR, Walsh, SR, Seaman, MS, Johnson, JA, Tucker, RP, Kleinjan, JA., et al. (2014). First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002). J Infect Dis 210: 1052-1061
104. Coughlan, L, Bradshaw, AC, Parker, AL, Robinson, H, White, K, Custers, J., et al. (2012). Ad5: Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous delivery. Mol Ther 20: 2268-2281
105. Mück-Häusl, M, Solanki, M, Zhang, W, Ruzsics, Z and Ehrhardt, A (2015). Ad 2.0: a novel recombineering platform for high-throughput generation of tailored adenoviruses. Nucleic Acids Res 43: e50
106. Bi, Y, Sun, L, Gao, D, Ding, C, Li, Z, Li, Y., et al. (2014). High-efficiency targeted editing of large viral genomes by RNA-guided nucleases. PLoS Pathog 10: e1004090
107. Abbink, P, Lemckert, AA, Ewald, BA, Lynch, DM, Denholtz, M, Smits, S., et al. (2007). Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 81: 4654-4663
108. Abbink, P, Maxfield, LF, Nganga, D, Borducchi, EN, Iampietro, MJ, Bricault, CA., et al. (2015). Construction and evaluation of novel rhesus monkey adenovirus vaccine vectors. J Virol 89: 1512-1522
109. Mastrangeli, A, Harvey, BG, Yao, J, Wolff, G, Kovesdi, I, Crystal, RG., et al. (1996).Sero-switch adenovirus-mediated in vivo gene transfer: circumvention of antiadenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. Hum Gene Ther 7: 79-87
110. Abrahamsen, K, Kong, HL, Mastrangeli, A, Brough, D, Lizonova, A, Crystal, RG., et al. (1997). Construction of an adenovirus type 7a E1A- vector. J Virol 71: 8946-8951
111. Brough, DE, Lizonova, A, Hsu, C, Kulesa, VA and Kovesdi, I (1996). A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J Virol 70: 6497-6501
112. Stone, D and Lieber, A (2006). New serotypes of adenoviral vectors. Curr Opin Mol Ther 8: 423-431
113. Sirena, D, Ruzsics, Z, Schaffner, W, Greber, UF and Hemmi, S (2005). The nucleotide sequence and a first generation gene transfer vector of species B human adenovirus serotype 3. Virology 343: 283-298
114. Stone, D, Ni, S, Li, ZY, Gaggar, A, DiPaolo, N, Feng, Q., et al. (2005). Development and assessment of human adenovirus type 11 as a gene transfer vector. J Virol 79: 5090-5104
115. Seshidhar Reddy, P, Ganesh, S, Limbach, MP, Brann, T, Pinkstaff, A, Kaloss, M., et al. (2003). Development of adenovirus serotype 35 as a gene transfer vector. Virology 311: 384-393
116. Hemminki, O, Diaconu, I, Cerullo, V, Pesonen, SK, Kanerva, A, Joensuu, T., et al. (2012). Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer. Mol Ther 20: 1821-1830
117. Creech, CB, Dekker, CL, Ho, D, Phillips, S, Mackey, S, Murray-Krezan, C., et al. (2013). Randomized, placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults. Hum Vaccin Immunother 9: 2548-2557
118. Vogels, R, Zuijdgeest, D, Van Meerendonk, M, Companjen, A, Gillissen, G, Sijtsma, J., et al. (2007). High-level expression from two independent expression cassettes in replication-incompetent adenovirus type 35 vector. J Gen Virol 88: 2915-2924
119. Kuhn, I, Harden, P, Bauzon, M, Chartier, C, Nye, J, Thorne, S., et al. (2008). Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS One 3: e2409
120. Di, Y, Seymour, L and Fisher, K (2014). Activity of a group B oncolytic adenovirus (ColoAd1) in whole human blood. Gene Ther 21: 440-443
121. Havenga, M, Vogels, R, Zuijdgeest, D, Radosevic, K, Mueller, S, Sieuwerts, M., et al. (2006). Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells. J Gen Virol 87: 2135-2143
122. Kahl, CA, Bonnell, J, Hiriyanna, S, Fultz, M, Nyberg-Hoffman, C, Chen, P., et al. (2010). Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vaccine vector based on rare human serotype 28. Vaccine 28: 5691-5702
123. Vogels, R, Zuijdgeest, D, Van Rijnsoever, R, Hartkoorn, E, Damen, I, De Béthune, MP., et al. (2003). Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 77: 8263-8271
124. Lemckert, AA, Grimbergen, J, Smits, S, Hartkoorn, E, Holterman, L, Berkhout, B., et al. (2006). Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity. J Gen Virol 87: 2891-2899
125. Teigler, JE, Iampietro, MJ and Barouch, DH (2012). Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeys. J Virol 86: 9590-9598
126. Tameris, M, Hokey, DA, Nduba, V, Sacarlal, J, Laher, F, Kiringa, G., et al. (2015). A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants. Vaccine 33: 2944-2954
127. Ouédraogo, A, Tiono, AB, Kargougou, D, Yaro, JB, Ouédraogo, E, Kaboré, Y., et al. (2013). A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age. PLoS One 8: e78679
128. Keefer, MC, Gilmour, J, Hayes, P, Gill, D, Kopycinski, J, Cheeseman, H., et al. (2012). A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One 7: e41936
129. Baden, LR, Walsh, SR, Seaman, MS, Tucker, RP, Krause, KH, Patel, A., et al. (2013). Firstin-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). J Infect Dis 207: 240-247
130. Gilbert, SC (2015). Adenovirus-vectored Ebola vaccines. Expert Rev Vaccines 14: 1347-1357
131. Baden, LR, Liu, J, Li, H, Johnson, JA, Walsh, SR, Kleinjan, JA., et al. (2015). Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans. J Infect Dis 211: 518-528
132. Zahn, R, Gillisen, G, Roos, A, Koning, M, Van Der Helm, E, Spek, D., et al. (2012). Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species. PLoS One 7: e44115
133. Johnson, MJ, Björkström, NK, Petrovas, C, Liang, F, Gall, JG, Loré, K., et al. (2014). Type I interferon-dependent activation of NK cells by rAd28 or rAd35, but not rAd5, leads to loss of vector-insert expression. Vaccine 32: 717-724
134. Dakin, RS, Parker, AL, Delles, C, Nicklin, SA and Baker, AH (2015). Efficient transduction of primary vascular cells by the rare adenovirus serotype 49 vector. Hum Gene Ther 26: 312-319
135. Alexander, J, Ward, S, Mendy, J, Manayani, DJ, Farness, P, Avanzini, JB., et al. (2012). Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin. PLoS One 7: e31177
136. Alexander, J, Mendy, J, Vang, L, Avanzini, JB, Garduno, F, Manayani, DJ., et al. (2013). Pre-clinical development of a recombinant, replication-competent adenovirus serotype 4 vector vaccine expressing HIV-1 envelope 1086 clade C. PLoS One 8: e82380
137. Gurwith, M, Lock, M, Taylor, EM, Ishioka, G, Alexander, J, Mayall, T., et al. (2013). Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study. Lancet Infect Dis 13: 238-250
138. Lemiale, F, Haddada, H, Nabel, GJ, Brough, DE, King, CR and Gall, JG (2007). Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41. Vaccine 25: 2074-2084
139. Jarecki-Khan, K and Unicomb, LE (1992). Seroprevalence of enteric and nonenteric adenoviruses in Bangladesh. J Clin Microbiol 30: 2733-2734
140. Saderi, H, Roustai, MH and Sabahi, F (2000). Antibodies to enteric adenoviruses (Ad40 and Ad41) in sera from Iranian children. J Clin Virol 16: 145-147
141. Ko, SY, Cheng, C, Kong, WP, Wang, L, Kanekiyo, M, Einfeld, D., et al. (2009). Enhanced induction of intestinal cellular immunity by oral priming with enteric adenovirus 41 vectors. J Virol 83: 748-756
142. Bangari, DS and Mittal, SK (2006). Development of nonhuman adenoviruses as vaccine vectors. Vaccine 24: 849-862
143. Ayalew, LE, Kumar, P, Gaba, A, Makadiya, N and Tikoo, SK (2015). Bovine adenovirus-3 as a vaccine delivery vehicle. Vaccine 33: 493-499
144. Hammond, JM, McCoy, RJ, Jansen, ES, Morrissy, CJ, Hodgson, AL and Johnson, MA (2000). Vaccination with a single dose of a recombinant porcine adenovirus expressing the classical swine fever virus gp55 (E2) gene protects pigs against classical swine fever. Vaccine 18: 1040-1050
145. Tuboly, T and Nagy, E (2001). Construction and characterization of recombinant porcine adenovirus serotype 5 expressing the transmissible gastroenteritis virus spike gene. J Gen Virol 82: 183-190
146. Fischer, L, Tronel, JP, Pardo-David, C, Tanner, P, Colombet, G, Minke, J., et al. (2002). Vaccination of puppies born to immune dams with a canine adenovirus-based vaccine protects against a canine distemper virus challenge. Vaccine 20: 3485-3497
147. Hu, R, Zhang, S, Fooks, AR, Yuan, H, Liu, Y, Li, H., et al. (2006). Prevention of rabies virus infection in dogs by a recombinant canine adenovirus type-2 encoding the rabies virus glycoprotein. Microbes Infect 8: 1090-1097
148. Greenall, SA, Tyack, SG, Johnson, MA and Sapats, SI (2010). Antibody fragments, expressed by a fowl adenovirus vector, are able to neutralize infectious bursal disease virus. Avian Pathol 39: 339-348
149. Brake, DA, McIlhaney, M, Miller, T, Christianson, K, Keene, A, Lohnas, G., et al. (2012). Human adenovirus-vectored foot-and-mouth disease vaccines: establishment of a vaccine product profile through in vitro testing. Dev Biol (Basel) 134: 123-133
150. Lopez-Gordo, E, Podgorski, II, Downes, N and Alemany, R (2014). Circumventing antivector immunity: potential use of nonhuman adenoviral vectors. Hum Gene Ther 25: 285-300
151. Kremer, EJ (2004). CAR chasing: canine adenovirus vectors-all bite and no bark?. J Gene Med 6 (suppl. 1): S139-S151
152. Soudais, C, Laplace-Builhe, C, Kissa, K and Kremer, EJ (2001). Preferential transduction of neurons by canine adenovirus vectors and their efficient retrograde transport in vivo. FASEB J 15: 2283-2285
153. Soudais, C, Skander, N and Kremer, EJ (2004). Long-term in vivo transduction of neurons throughout the rat CNS using novel helper-dependent CAV-2 vectors. FASEB J 18: 391-393
154. Silva, AC, Fernandes, P, Sousa, MF and Alves, PM (2014). Scalable production of adenovirus vectors. Methods Mol Biol 1089: 175-196
155. Puig, M, Piedra, J, Miravet, S and Segura, MM (2014). Canine adenovirus downstream processing protocol. Methods Mol Biol 1089: 197-210
156. Fernandes, P, Almeida, AI, Kremer, EJ, Alves, PM and Coroadinha, AS (2015). Canine helper-dependent vectors production: implications of Cre activity and co-infection on adenovirus propagation. Sci Rep 5: 9135
157. Tandon, M, Sharma, A, Vemula, SV, Bangari, DS and Mittal, SK (2012). Sequential administration of bovine and human adenovirus vectors to overcome vector immunity in an immunocompetent mouse model of breast cancer. Virus Res 163: 202-211
158. Bangari, DS, Shukla, S and Mittal, SK (2005). Comparative transduction efficiencies of human and nonhuman adenoviral vectors in human, murine, bovine, and porcine cells in culture. Biochem Biophys Res Commun 327: 960-966
159. Nguyen, T, Nery, J, Joseph, S, Rocha, C, Carney, G, Spindler, K., et al. (1999). Mouse adenovirus (MAV-1) expression in primary human endothelial cells and generation of a full-length infectious plasmid. Gene Ther 6: 1291-1297
160. Lenaerts, L, McVey, JH, Baker, AH, Denby, L, Nicklin, S, Verbeken, E., et al. (2009). Mouse adenovirus type 1 and human adenovirus type 5 differ in endothelial cell tropism and liver targeting. J Gene Med 11: 119-127
161. Ying, B, Smith, K and Spindler, KR (1998). Mouse adenovirus type 1 early region 1A is dispensable for growth in cultured fibroblasts. J Virol 72: 6325-6331
162. Van Olphen, AL, Tikoo, SK and Mittal, SK (2002). Characterization of bovine adenovirus type 3 E1 proteins and isolation of E1-expressing cell lines. Virology 295: 108-118
163. Zakhartchouk, A, Zhou, Y and Tikoo, SK (2003). A recombinant E1-deleted porcine adenovirus-3 as an expression vector. Virology 313: 377-386
164. Cauthen, AN, Brown, CC and Spindler, KR (1999). In vitro and in vivo characterization of a mouse adenovirus type 1 early region 3 null mutant. J Virol 73: 8640-8646
165. Reddy, PS, Idamakanti, N, Hyun, BH, Tikoo, SK and Babiuk, LA (1999). Development of porcine adenovirus-3 as an expression vector. J Gen Virol 80: 563-570
166. Reddy, PS, Idamakanti, N, Chen, Y, Whale, T, Babiuk, LA, Mehtali, M., et al. (1999). Replication-defective bovine adenovirus type 3 as an expression vector. J Virol 73: 9137-9144
167. Li, X, Bangari, DS, Sharma, A and Mittal, SK (2009). Bovine adenovirus serotype 3 utilizes sialic acid as a cellular receptor for virus entry. Virology 392: 162-168
168. Lenaerts, L, Van Dam, W, Persoons, L and Naesens, L (2012). Interaction between mouse adenovirus type 1 and cell surface heparan sulfate proteoglycans. PLoS One 7: e31454
169. Sharma, A, Bangari, DS, Tandon, M, Hogenesch, H and Mittal, SK (2010). Evaluation of innate immunity and vector toxicity following inoculation of bovine, porcine or human adenoviral vectors in a mouse model. Virus Res 153: 134-142
170. Sharma, A, Tandon, M, Ahi, YS, Bangari, DS, Vemulapalli, R and Mittal, SK (2010). Evaluation of cross-reactive cell-mediated immune responses among human, bovine and porcine adenoviruses. Gene Ther 17: 634-642
171. Roy, S, Medina-Jaszek, A, Wilson, MJ, Sandhu, A, Calcedo, R, Lin, J., et al. (2011). Creation of a panel of vectors based on ape adenovirus isolates. J Gene Med 13: 17-25
172. Cohen, CJ, Xiang, ZQ, Gao, GP, Ertl, HC, Wilson, JM and Bergelson, JM (2002). Chimpanzee adenovirus CV-68 adapted as a gene delivery vector interacts with the coxsackievirus and adenovirus receptor. J Gen Virol 83: 151-155
173. Xiang, Z, Li, Y, Cun, A, Yang, W, Ellenberg, S, Switzer, WM., et al. (2006). Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg Infect Dis 12: 1596-1599
174. Quinn, KM, Da Costa, A, Yamamoto, A, Berry, D, Lindsay, RW, Darrah, PA., et al. (2013). Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization. J Immunol 190: 2720-2735
175. Farina, SF, Gao, GP, Xiang, ZQ, Rux, JJ, Burnett, RM, Alvira, MR., et al. (2001). Replication-defective vector based on a chimpanzee adenovirus. J Virol 75: 11603-11613
176. Roy, S, Gao, G, Lu, Y, Zhou, X, Lock, M, Calcedo, R., et al. (2004). Characterization of a family of chimpanzee adenoviruses and development of molecular clones for gene transfer vectors. Hum Gene Ther 15: 519-530
177. Colloca, S, Barnes, E, Folgori, A, Ammendola, V, Capone, S, Cirillo, A., et al. (2012). Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 4: 115ra2
178. Barnes, E, Folgori, A, Capone, S, Swadling, L, Aston, S, Kurioka, A., et al. (2012). Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 4: 115ra1
179. OHara, GA, Duncan, CJ, Ewer, KJ, Collins, KA, Elias, SC, Halstead, FD., et al. (2012). Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis 205: 772-781
180. Antrobus, RD, Coughlan, L, Berthoud, TK, Dicks, MD, Hill, AV, Lambe, T., et al. (2014). Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens. Mol Ther 22: 668-674
181. Stanley, DA, Honko, AN, Asiedu, C, Trefry, JC, Lau-Kilby, AW, Johnson, JC., et al. (2014). Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med 20: 1126-1129
182. Tan, PK, Michou, AI, Bergelson, JM and Cotten, M (2001). Defining CAR as a cellular receptor for the avian adenovirus CELO using a genetic analysis of the two viral fibre proteins. J Gen Virol 82: 1465-1472
183. Michou, AI, Lehrmann, H, Saltik, M and Cotten, M (1999). Mutational analysis of the avian adenovirus CELO, which provides a basis for gene delivery vectors. J Virol 73: 1399-1410
184. Ojkic, D and Nagy, E (2003). Antibody response and virus tissue distribution in chickens inoculated with wild-type and recombinant fowl adenoviruses. Vaccine 22: 42-48
185. Sheppard, M, Werner, W, McCoy, RJ and Johnson, MA (1998). The major late promoter and bipartite leader sequence of fowl adenovirus. Arch Virol 143: 537-548
186. Corredor, JC and Nagy, E (2010). The non-essential left end region of the fowl adenovirus 9 genome is suitable for foreign gene insertion/replacement. Virus Res 149: 167-174
187. Cherenova, LV, Logunov, DY, Shashkova, EV, Shmarov, MM, Verkhovskaya, LV, Neugodova, GL., et al. (2004). Recombinant avian adenovirus CELO expressing the human interleukin-2: characterization in vitro, in ovo and in vivo. Virus Res 100: 257-261
188. Shashkova, EV, Cherenova, LV, Kazansky, DB and Doronin, K (2005). Avian adenovirus vector CELO-TK displays anticancer activity in human cancer cells and suppresses established murine melanoma tumors. Cancer Gene Ther 12: 617-626
189. Logunov, DY, Ilyinskaya, GV, Cherenova, LV, Verhovskaya, LV, Shmarov, MM, Chumakov, PM., et al. (2004). Restoration of p53 tumor-suppressor activity in human tumor cells in vitro and in their xenografts in vivo by recombinant avian adenovirus CELO-p53. Gene Ther 11: 79-84
190. Both, GW (2004). Ovine atadenovirus: a review of its biology, biosafety profile and application as a gene delivery vector. Immunol Cell Biol 82: 189-195
191. Xu, ZZ, Hyatt, A, Boyle, DB and Both, GW (1997). Construction of ovine adenovirus recombinants by gene insertion or deletion of related terminal region sequences. Virology 230: 62-71
192. Khatri, A, Xu, ZZ and Both, GW (1997). Gene expression by atypical recombinant ovine adenovirus vectors during abortive infection of human and animal cells in vitro. Virology 239: 226-237
193. Hofmann, C, Löser, P, Cichon, G, Arnold, W, Both, GW and Strauss, M (1999). Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo. J Virol 73: 6930-6936
194. Löser, P, Hofmann, C, Both, GW, Uckert, W and Hillgenberg, M (2003). Construction, rescue, and characterization of vectors derived from ovine atadenovirus. J Virol 77: 11941-11951
195. Both, GW, Cameron, F, Collins, A, Lockett, LJ and Shaw, J (2007). Production and release testing of ovine atadenovirus vectors. Methods Mol Med 130: 69-90
196. Martiniello-Wilks, R, Dane, A, Voeks, DJ, Jeyakumar, G, Mortensen, E, Shaw, JM., et al. (2004). Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that imitates the development of human disease. J Gene Med 6: 43-54
197. Tang, R, Li, K, Wilson, M, Both, GW, Taylor, JA and Young, SL (2012). Potent antietumor immunity in mice induced by vaccination with an ovine atadenovirus vector. J Immunother 35: 32-41
198. Fraser, CK, Diener, KR, Lousberg, EL, Both, GW, Ward, L, Brown, MP., et al. (2010). Induction of both cellular and humoral immunity following a rational prime-boost immunization regimen that incorporates recombinant ovine atadenovirus and fowlpox virus. Clin Vaccine Immunol 17: 1679-1686
199. Bridgeman, A, Roshorm, Y, Lockett, LJ, Xu, ZZ, Hopkins, R, Shaw, J., et al. (2009). Ovine atadenovirus, a novel and highly immunogenic vector in prime-boost studies of a candidate HIV-1 vaccine. Vaccine 28: 474-483
200. Doszpoly, A, Wellehan, JF Jr, Childress, AL, Tarján, ZL, Kovács, ER, Harrach, B., et al. (2013). Partial characterization of a new adenovirus lineage discovered in testudinoid turtles. Infect Genet Evol 17: 106-112
201. Cortés-Hinojosa, G, Gulland, FM, Goldstein, T, Venn-Watson, S, Rivera, R, Waltzek, TB., et al. (2015). Phylogenomic characterization of California sea lion adenovirus-1. Infect Genet Evol 31: 270-276
202. Wigand, R (1987). Pitfalls in the identification of adenoviruses. J Virol Methods 16: 161-169
203. Kajon, A and Wadell, G (1994). Genome analysis of South American adenovirus strains of serotype 7 collected over a 7-year period. J Clin Microbiol 32: 2321-2323
204. Guy, JS and Barnes, HJ (1997). Characterization of an avian adenovirus associated with inclusion body hepatitis in day-old turkeys. Avian Dis 41: 726-731
205. Benkö, M, Harrach, B and DHalluin, JC (1990). Molecular cloning and physical mapping of the DNA of bovine adenovirus serotype 4; study of the DNA homology among bovine, human and porcine adenoviruses. J Gen Virol 71: 465-469
206. Lu, X and Erdman, DD (2006). Molecular typing of human adenoviruses by PCR and sequencing of a partial region of the hexon gene. Arch Virol 151: 1587-1602
207. Günes, A, Marek, A, Grafl, B, Berger, E and Hess, M (2012). Real-time PCR assay for universal detection and quantitation of all five species of fowl adenoviruses (FAdV-A to FAdV-E). J Virol Methods 183: 147-153
208. Wellehan, JF, Johnson, AJ, Harrach, B, Benkö, M, Pessier, AP, Johnson, CM., et al. (2004). Detection and analysis of six lizard adenoviruses by consensus primer PCR provides further evidence of a reptilian origin for the atadenoviruses. J Virol 78: 13366-13369
209. Phan, TG, Vo, NP, Boros, Á, Pankovics, P, Reuter, G, Li, OT., et al. (2013). The viruses of wild pigeon droppings. PLoS One 8: e72787